Murty Pharmaceuticals Incorporated (MPI)

MPI was founded in 1995 by its President and Scientific Director, Dr. Ram Murty. The firm was formed to undertake research and development work for the advancement and commercialization of pharmaceutical innovations. Murty Pharmaceuticals, Inc.("MPI") is a pharmaceutical research and development firm that specializes in novel formulations of new and existing chemical entities conducted in strict conformance with applicable cGMPs. For solid oral dosage forms, MPI can develop robust manufacturing processes for exhibit and commercial batches, and can manufacture clinical supplies to meet any client requirements. In addition, MPI provides regulatory support for submissions of NDAs, ANDAs, INDs, and CMCs from the onset, thereby reducing the need for redundant studies and reducing total costs of development. Through scientific collaboration and strategic partnerships, MPI has conducted patentable research and developed several proprietary drug products and delivery systems, including: Microencapsulation Controlled release  Sublingual  Transdermal gels  MPI offers a wide spectrum of services and expertise in scientific, professional, manufacturing, quality control, and regulatory fields in compliance with applicable cGMP/GLP regulations mandated by the FDA.  Services include formulation development, drug delivery design, analytical method development/validation, drug stability assessment, clinical supply manufacturing, labeling, packaging, and shipping. For small scale isolation, extraction, and purification of drug moieties, the company possesses state-of-the-art supercritical fluid (SCF) units. In addition, MPI provides documentation and regulatory support for DMF preparations as well as IND, NDA, and ANDA submissions.